Cytori Appoints David M. Rickey as Chairman of the Board of Directors

  Cytori Appoints David M. Rickey as Chairman of the Board of Directors

Business Wire

SAN DIEGO -- July 9, 2013

Cytori Therapeutics’ (NASDAQ: CYTX) Board of Directors has appointed David M.
Rickey to serve as the Chairman of the Board. Mr. Rickey has served on
Cytori’s Board as a Director for more than 13 years, and he also serves as the
Chairman of the Compensation Committee of the Board. Lloyd H. Dean will
continue to serve as an independent member of the Company’s Board of
Directors, and as a member of the Governance and Nominating Committee.

“Cytori’s cell therapy platform has the potential to bring about an entirely
new class of therapeutics that are innovative and cost-effective,” said Mr.
Rickey. “In the role as chair, my priorities will be to represent the
interests of our shareholders and to help guide Cytori’s growth as it aims to
become a leading independent global biotechnology organization.”

“I look forward to continuing my service with Cytori Therapeutics and guiding
their future success,” said Mr. Dean. Mr. Dean is a national leader in
healthcare and serves as the President/CEO of Dignity Health, one of the
nation’s five largest health systems. He requested the transition to
accommodate the growing demands associated with ensuring that both Dignity
Health and the nation are fully prepared for the January 2014 implementation
of the Affordable Care Act.

“Mr. Rickey has played a critical role in Cytori’s growth by providing us with
invaluable operational and governance experience during his 13 years as a
director,” said Chris Calhoun, CEO of Cytori. “We are grateful to Mr. Dean for
his leadership and service as Chairman for the past two years, and look
forward his continued service to Cytori and our shareholders into the future.”

David M. Rickey has served as a Director of the Company since November 1999.
Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits
Corporation (AMCC) from February 1996 to March 2005. Mr. Rickey served on the
Board of Directors of AMCC from February 1996 to March 2005, and as its
Chairman of the Board from August 2000 to March 2005. Mr. Rickey also served
as a Director of AMI Semiconductor, Inc. from 2000 to 2006 and was a Director
of Netlist, Inc. from 2005 to 2008, as well as several private technology
companies. He holds a B.S. from Marietta College, a B.S. from Columbia
University and an M.S. from Stanford University.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution® System product family. www.cytori.com

Contact:

Cytori Therapeutics
Investors
Tom Baker, +1-858-875-5258
tbaker@cytori.com
or
Media
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com
 
Press spacebar to pause and continue. Press esc to stop.